NIKKEI 225
38,670.04 -33.47 (-0.09%) HANG SENG
18,476.80 0.00 (0.00%) CRUDE OIL
75.67 +0.12 (+0.16%) GOLD FUTURES
2,392.80 +1.90 (+0.08%) DOW
38,886.17 +78.84 (+0.20%) Bitcoin GBP
55,340.31 -226.74 (-0.41%)
GILD Jan 2026 50.000 call
| Previous close | 15.54 |
| Open | 15.54 |
| Bid | 15.65 |
| Ask | 16.90 |
| Strike | 50.00 |
| Expiry date | 2026-01-16 |
| Day's range | 15.54 - 15.54 |
| Contract range | N/A |
| Volume | |
| Open interest | 156 |
ZacksInvestors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Business WireGilead Announces New England Journal of Medicine Publication of Data that Demonstrate Bulevirtide with PegIFN Achieved Post-Treatment Undetectable HDV RNA
FOSTER CITY, Calif., June 06, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from the Phase 2b MYR204 open-label study assessing the efficacy and safety of the first-in-class entry inhibitor bulevirtide as monotherapy and in combination with pegylated interferon alfa-2a (PegIFN), in adults living with compensated chronic hepatitis delta virus (HDV) infection. Published in the New England Journal of Medicine (NEJM), the data demonstrate that the investigational combination of bul
Business WireGilead’s Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in Primary Biliary Cholangitis
FOSTER CITY, Calif., June 05, 2024--Gilead Sciences, Inc. (Nasdaq: GILD), following the recent acquisition of CymaBay Therapeutics, Inc., today announced two-year interim results from the ongoing ASSURE study of investigational seladelpar for the treatment of primary biliary cholangitis (PBC), a rare, chronic inflammatory liver disease. The two-year interim analysis includes people living with PBC who participated in any prior clinical studies of seladelpar (legacy studies) and participants from
